International Journal of Head and Neck Surgery

Register      Login

VOLUME 8 , ISSUE 2 ( April-June, 2017 ) > List of Articles


Head and Neck Cancer Research Ethics: A Primer

Joshua D Smith, Kayte Spector-Bagdady, Andrew G Shuman

Citation Information : Smith JD, Spector-Bagdady K, Shuman AG. Head and Neck Cancer Research Ethics: A Primer. Int J Head Neck Surg 2017; 8 (2):49-56.

DOI: 10.5005/jp-journals-10001-1306

License: CC BY 3.0

Published Online: 01-12-2012

Copyright Statement:  Copyright © 2017; The Author(s).


How to cite this article

Smith JD, Spector-Bagdady K, Shuman AG. Head and Neck Cancer Research Ethics: A Primer. Int J Head Neck Surg 2017;8(2):49-56.

  1. Collaborative clinical trials. N Engl J Med 2011 Mar;364(9):789-791.
  2. Ethical and scientific implications of the globalization of clinical research. N Engl J Med 2009 Feb;360(8):816-823.
  3. Targeted or whole genome sequencing of formalin fixed tissue samples: potential applications in cancer genomics. Oncotarget 2015 Sep;6(28):25943-25961.
  4. Fusing randomized trials with big data. The key to self-learning health care systems? JAMA 2015 Aug;314(8):767-768.
  5. Transforming from centers of learning to learning health systems: the challenge for academic health centers. JAMA 2014 Mar;311(11):1109-1110.
  6. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016;375(19):1856-1867.
  7. PET-CT surveillance versus neck dissection in advanced head and neck cancer. N Engl J Med 2016;374:1444-1454.
  8. Elective versus therapeutic neck dissection in node-negative oral cancer. N Engl J Med 2015 Nov;373(6):521-529.
  9. Differential compensation mechanisms define resistance to PI3K inhibitors in PICK3CA amplified HNSCC. Otorhinolaryngol Head Neck Surg 2016;1(2):44-50.
  10. Changing the paradigm: the potential for targeted therapy in laryngeal squamous cell carcinoma. Cancer Biol Med 2016 Mar;13(1):87-100.
  11. Identification of targetable ERBB2 aberrations in head and neck squamous cell carcinoma. JAMA Otolaryngol Head Neck Surg 2016 Jun;142(6):559-567.
  12. What makes clinical research ethical? JAMA 2000;283(20):2701-2711.
  13. The Tuskegee syphilis study. N Engl J Med 1973;289:730-731.
  14. Ethically impossible: STD research in Guatemala from 1946 to 1948, 2011. Available from:
  15. The Nuremberg Code. JAMA 1996 Nov;276(20):1691.
  16. Declaration of Helsinki. JAMA 2013 Nov;310(20):2191-2194.
  17. Available from:
  18. Available from:
  19. Available from:
  20. Available from:
  21. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: Ethical and scientific issues. Ann Intern Med 2000 Sep;133(6):455-463.
  22. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: Practical issues and specific cases. Ann Intern Med 2000 Sep;133(6):464-470.
  23. Denial of effective treatment and poor quality of clinical information in placebo controlled trials of ondansetron for postoperative nausea and vomiting: a review of published trials. BMJ 1995 Sep;311(7009):844-846.
  24. Equipoise and the ethics of clinical research. N Engl J Med 1987 Jul;317(3):141-145.
  25. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006;295(18):2164-2167.
  26. Increased incidence of thyroid carcinoma in France: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Committee. Thyroid 2004 Dec;14(12):1056-1060.
  27. Management of low-risk differentiated thyroid cancer. Endocr Pract 2007 Sep;13(5):498-512.
  28. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid 2014 Jan;24(1):27-34.
  29. Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes. World J Surg 2010 Jun;34(6):1222-1231.
  30. Patient perspective on watchful waiting/active surveillance for localized prostate cancer. J Am Board Fam Med 2012 Nov-Dec;25(6):736-770.
  31. The ethics of disclosure and counseling of patient with thyroid cancer. JAMA Otolaryngol Head Neck Surg 2015 Nov;141(11):957-958.
  32. Trends in National Institutes of Health funding for clinical trials registered in . JAMA 2015 Dec;314(23):2566-2567.
  33. Industry-funded clinical trials: beneficial or harmful? Clin Res Regul Aff 2015;32(4):109-112.
  34. Characteristics of NIH- and industry-sponsored head and neck cancer trials. Laryngoscope 2016 Sep;126(9): 300-303.
  35. Hard-wired bias: how even double-blinded, randomized controlled trials can be skewed from the start. Mayo Clin Proc 2015 Sep;90(9):1171-1175.
  36. Why disclosure? J Gen Intern Med 2006 Jul;21(7):1003-1004.
  37. Professional medical associations and their relationship with industry: a proposal for controlling conflict of interest. JAMA 2009 Apr;301(13):1367-1372.
  38. Clinical practice guideline development manual: a quality-driven approach for translating evidence into action. Otolaryngol Head Neck Surg 2009 Jun;140 (Suppl 1):S1-S43.
  39. Conflicts of interest reporting in otolaryngology clinical practice guidelines. Otolaryngol Head Neck Surg 2013 Aug;149(2):187-191.
  40. Conflict of interest in clinical practice guideline development: a systematic review. PLoS One 2011;6:e25153.
  41. Clinical Practice Guidelines, 2017. Available from:
  42. Studying surgical innovations: challenges of the randomized controlled trial. J Minim Invasive Gynecol 2015 May-Jun;22(4):573-582.
  43. Clinical research in surgery: threats and opportunities. Eur Surg Res 2014;53(1-4):95-107.
  44. Surgical innovation, industry partnership, and the enemy within. Head Neck 2014 Apr;36(4):461-465.
  45. Surgical innovation: the ethical agenda. Medicine 2016 Jun;95(25):e3790.
  46. Surgical innovation and ethical dilemmas: a panel discussion. Cleve Clin J Med 2008 Nov;75(Suppl 6):S13-S21.
  47. Surgical innovation or surgical evolution: an ethical and practical guide to handling novel neurosurgical procedures. J Neurosurg 2004 Jan;100(1):2-7.
  48. New technology and the orthopaedic surgeon: are you protecting your patients? Clin Orthop Relat Res 2004 Dec;429:338-341.
  49. Emergency innovation: implications for the trauma surgeon. J Trauma 2009 Dec;67(6):1443-1447.
  50. TransOral Robotic Surgery (TORS), 2017. Available from:
  51. Transoral robotic surgery: supraglottic laryngectomy in a canine model. Laryngoscope 2005 Jul;115(7):1315-1319.
  52. Robot-assisted pharyngeal and laryngeal microsurgery: results of robotic cadaver dissections. Laryngoscope 2005 Jun;115(6):1003-1008.
  53. Assessment of intraoperative safety in transoral robotic surgery. Laryngoscope 2006 Feb;116(2):165-168.
  54. Oropharyneal cancer: a case for single modality treatment with transoral laser microsurgery. Arch Otolaryngol Head Neck Surg 2009 Dec;135(12):1225-1230.
  55. Robotic-assisted surgery for primary or recurrent oropharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 2010;136(4):380-384.
  56. Discussion paper, Robotically-Assisted Surgical Devices, 2015. Available from:
  57. Transoral robotic surgery: disruptive or sustaining innovation? Arch Surg 2010 Sep;145(9):907-908.
  58. Elements of informed consent, 2017. Available from:
  59. Informed consent: issues and challenges. J Adv Pharm Technol Res 2013 Jul-Sep;4(3):134-140.
  60. Clinical trials and medical care: defining the therapeutic misconception. PLoS Med 2007 Nov;4(11):e324.
  61. Patients' expectations about effects of chemotherapy for advanced cancer. N Engl J Med 2012 Oct;367(17):1616-1625.
  62. Two models of implementing informed consent. Arch Intern Med 1988 Jun;148(6):1385-1389.
  63. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. The Lancet Oncology 2015;16(13):1324-1334.
  64. Available from:
  65. Revisiting the therapeutic misconception in an era of precision oncology. Under Review.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.